# Botulinum Toxin Type A for Injection (HengLi®) in the Treatment of Trigeminal Neuralgia

> **NCT06410859** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **LKGS_277** · enrollment: 240 (estimated)

## Conditions studied

- Trigeminal Neuralgia

## Interventions

- **DRUG:** Botulinum Toxin Type A for Injection,also known as "HengLi®"

## Key facts

- **NCT ID:** NCT06410859
- **Lead sponsor:** LKGS_277
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2024-04-25
- **Primary completion:** 2026-06-30
- **Final completion:** 2026-06-30
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2024-05-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06410859

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06410859, "Botulinum Toxin Type A for Injection (HengLi®) in the Treatment of Trigeminal Neuralgia". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT06410859. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*